| Mr David Thomas Abel Sr, CRNA | |
|
415 N Center St, Suite 201, Hickory, NC 28601-5057 | |
| (828) 327-8105 | |
| Not Available |
| Full Name | Mr David Thomas Abel Sr |
|---|---|
| Gender | Male |
| Speciality | Certified Registered Nurse Anesthetist (crna) |
| Experience | 13 Years |
| Location | 415 N Center St, Hickory, North Carolina |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1194026120 | NPI | - | NPPES |
| 8053995 | Medicaid | NC |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 367500000X | Nurse Anesthetist, Certified Registered | 087386 (North Carolina) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Frye Regional Medical Center | Hickory, NC | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| East Carolina Anesthesia Associates Pllc | 5092720813 | 464 |
| Caldwell Memorial Hospital Inc | 5395646970 | 150 |
News Archive
AusBiotech has kicked off its annual conference with a hugely successful Australasian Life Sciences Investment Summit 2010 in Melbourne today. The premier life science investment conference for Australia and the Asia-Pacific region attracted 150 investors from more than 100 organisations to hear 39 selected Australian biotechnology companies.
Galectin Therapeutics, the Cancer Centre at the Cliniques universitaires Saint-Luc and the Ludwig Institute for Cancer Research (LICR) announced today that they will initiate a Phase 1/2 safety and efficacy trial testing a novel treatment combination in patients with advanced metastatic melanoma.
Duchenne muscular dystrophy (DMD) is a muscular disease that shows symptoms in early childhood and causes progressive atrophy and eventual death. There is little in terms of treatment, partly because of poor understanding of how DMD develops, although it is known that abnormal expression of the protein dystrophin is at fault.
Addition of chemotherapy to radiotherapy significantly improves outcomes in patients with nonmetastatic nasopharyngeal carcinoma, shows a meta-analysis.
RUDN University discovered the features of liver macrophages activation during its regeneration. In future, it can be used to develop new treatment methods for liver cirrhosis. The results are published in the Biomedicine.
› Verified 7 days ago
| Entity Name | Caldwell Memorial Hospital Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1740312552 PECOS PAC ID: 5395646970 Enrollment ID: O20040219000941 |
News Archive
AusBiotech has kicked off its annual conference with a hugely successful Australasian Life Sciences Investment Summit 2010 in Melbourne today. The premier life science investment conference for Australia and the Asia-Pacific region attracted 150 investors from more than 100 organisations to hear 39 selected Australian biotechnology companies.
Galectin Therapeutics, the Cancer Centre at the Cliniques universitaires Saint-Luc and the Ludwig Institute for Cancer Research (LICR) announced today that they will initiate a Phase 1/2 safety and efficacy trial testing a novel treatment combination in patients with advanced metastatic melanoma.
Duchenne muscular dystrophy (DMD) is a muscular disease that shows symptoms in early childhood and causes progressive atrophy and eventual death. There is little in terms of treatment, partly because of poor understanding of how DMD develops, although it is known that abnormal expression of the protein dystrophin is at fault.
Addition of chemotherapy to radiotherapy significantly improves outcomes in patients with nonmetastatic nasopharyngeal carcinoma, shows a meta-analysis.
RUDN University discovered the features of liver macrophages activation during its regeneration. In future, it can be used to develop new treatment methods for liver cirrhosis. The results are published in the Biomedicine.
› Verified 7 days ago
| Entity Name | East Carolina Anesthesia Associates Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1205996519 PECOS PAC ID: 5092720813 Enrollment ID: O20060215000791 |
News Archive
AusBiotech has kicked off its annual conference with a hugely successful Australasian Life Sciences Investment Summit 2010 in Melbourne today. The premier life science investment conference for Australia and the Asia-Pacific region attracted 150 investors from more than 100 organisations to hear 39 selected Australian biotechnology companies.
Galectin Therapeutics, the Cancer Centre at the Cliniques universitaires Saint-Luc and the Ludwig Institute for Cancer Research (LICR) announced today that they will initiate a Phase 1/2 safety and efficacy trial testing a novel treatment combination in patients with advanced metastatic melanoma.
Duchenne muscular dystrophy (DMD) is a muscular disease that shows symptoms in early childhood and causes progressive atrophy and eventual death. There is little in terms of treatment, partly because of poor understanding of how DMD develops, although it is known that abnormal expression of the protein dystrophin is at fault.
Addition of chemotherapy to radiotherapy significantly improves outcomes in patients with nonmetastatic nasopharyngeal carcinoma, shows a meta-analysis.
RUDN University discovered the features of liver macrophages activation during its regeneration. In future, it can be used to develop new treatment methods for liver cirrhosis. The results are published in the Biomedicine.
› Verified 7 days ago
| Entity Name | Butlak Anesthesia Solutions Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1013207679 PECOS PAC ID: 5597942946 Enrollment ID: O20110611000002 |
News Archive
AusBiotech has kicked off its annual conference with a hugely successful Australasian Life Sciences Investment Summit 2010 in Melbourne today. The premier life science investment conference for Australia and the Asia-Pacific region attracted 150 investors from more than 100 organisations to hear 39 selected Australian biotechnology companies.
Galectin Therapeutics, the Cancer Centre at the Cliniques universitaires Saint-Luc and the Ludwig Institute for Cancer Research (LICR) announced today that they will initiate a Phase 1/2 safety and efficacy trial testing a novel treatment combination in patients with advanced metastatic melanoma.
Duchenne muscular dystrophy (DMD) is a muscular disease that shows symptoms in early childhood and causes progressive atrophy and eventual death. There is little in terms of treatment, partly because of poor understanding of how DMD develops, although it is known that abnormal expression of the protein dystrophin is at fault.
Addition of chemotherapy to radiotherapy significantly improves outcomes in patients with nonmetastatic nasopharyngeal carcinoma, shows a meta-analysis.
RUDN University discovered the features of liver macrophages activation during its regeneration. In future, it can be used to develop new treatment methods for liver cirrhosis. The results are published in the Biomedicine.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Mr David Thomas Abel Sr, CRNA 415 N Center St, Suite 201, Hickory, NC 28601-5057 Ph: (828) 327-8105 | Mr David Thomas Abel Sr, CRNA 415 N Center St, Suite 201, Hickory, NC 28601-5057 Ph: (828) 327-8105 |
News Archive
AusBiotech has kicked off its annual conference with a hugely successful Australasian Life Sciences Investment Summit 2010 in Melbourne today. The premier life science investment conference for Australia and the Asia-Pacific region attracted 150 investors from more than 100 organisations to hear 39 selected Australian biotechnology companies.
Galectin Therapeutics, the Cancer Centre at the Cliniques universitaires Saint-Luc and the Ludwig Institute for Cancer Research (LICR) announced today that they will initiate a Phase 1/2 safety and efficacy trial testing a novel treatment combination in patients with advanced metastatic melanoma.
Duchenne muscular dystrophy (DMD) is a muscular disease that shows symptoms in early childhood and causes progressive atrophy and eventual death. There is little in terms of treatment, partly because of poor understanding of how DMD develops, although it is known that abnormal expression of the protein dystrophin is at fault.
Addition of chemotherapy to radiotherapy significantly improves outcomes in patients with nonmetastatic nasopharyngeal carcinoma, shows a meta-analysis.
RUDN University discovered the features of liver macrophages activation during its regeneration. In future, it can be used to develop new treatment methods for liver cirrhosis. The results are published in the Biomedicine.
› Verified 7 days ago
Mr. Hermann Curt Spiegel, CRNA Nurse Anesthetist - CR Medicare: Not Enrolled in Medicare Practice Location: 242a 9th Ave Dr Ne, Hickory, NC 28601 Phone: 828-327-6673 | |
Tracy A. Ellingson, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 242a 9th Ave Dr Ne, Hickory, NC 28601 Phone: 828-327-6673 | |
Mrs. Terry C Wellman, CRNA Nurse Anesthetist - CR Medicare: Medicare Enrolled Practice Location: 10 3rd Ave Ne Ste 200, Hickory, NC 28601 Phone: 828-327-8105 Fax: 828-327-4245 | |
Mr. Donald E Lowe, CRNA Nurse Anesthetist - CR Medicare: Not Enrolled in Medicare Practice Location: 415 N Center St, Ste 201, Hickory, NC 28601 Phone: 828-327-8105 Fax: 828-327-4245 | |
Ida Louise Goodnight, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 810 Fairgrove Church Rd, Hickory, NC 28602 Phone: 828-326-3809 Fax: 828-326-3371 | |
Katherine D Dellinger, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 415 N Center St, Suite 201, Hickory, NC 28601 Phone: 828-327-8105 Fax: 828-327-4245 | |
Robert A Hartman, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 415 N Center St, Ste 201, Hickory, NC 28601 Phone: 828-327-8105 Fax: 828-327-4245 |